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Abstract
Purpose The aim of the study was to determine the
aetiology of FDG uptake in vaginal tampons (VT), a
known artefact in premenopausal women evaluated by
PET/CT.
Methods This Institutional Review Board approved study
consisted of retrospective and prospective parts. The
retrospective analysis included 685 women examined
between January 2008 and December 2009 regarding VT
presence. PET/CT images were analysed to determine the
localization and the standardized uptake value (SUV) of
VTs. We prospectively recruited 24 women (20–48 years
old) referred for staging or follow-up in an oncology setting
between February and April 2010, who were provided a
commercial VT to be used during the entire examination
after obtaining written informed consent. After image
acquisition, VTs were individually analysed for creatinine
concentration and blood traces. Statistical significance was
tested with the Mann-Whitney U test.
Results In the retrospective part, 38 of 685 women were
found to have a VT of which 17 (45%) were FDG positive.
A statistically significant correlation was found between
FDG activity and VT position below the pubococcygeal
line (PCL) (13±11.2 mm). In the prospective study, 7 of 24
(29%) women had increased FDG activity in their VTs
(SUV 18.8±11 g/ml) but were not menstruating. FDG-
positive VTs were significantly lower in position (14.6±
11.4 mm,below the PCL) than FDG-negative VTs
(p=0.039). The creatinine concentration was significantly
increased in all seven positive VTs (931±615 μmol/l).
Conclusion FDG uptake in VTs is caused by urine
contamination, which is likely related to localization below
the PCL resulting in contact with urine during voiding.
Keywords FDG PET/CT. Vaginal tampon .
Misplacement . Urinary contamination . Spillover artefact .
FDG contamination
Introduction
Increased 18F-fluorodeoxyglucose (FDG) activity in vaginal
tampons (VT) is a commonly encountered artefact in PET/
CT [1, 2]. Moderately increased FDG activity is observed
frequently in the uterine cavity during menstrual bleeding
[3–5]; thus, FDG activity in VTs due to menstrual blood is
plausible. However, in routine PET/CT, FDG activity in
VTs is often in the range of brain or urine activity, rather
than the blood pool, and localized mainly at the base of the
VT. Although VTs are not expected to contain urine in
cases of proper intravaginal placement, we hypothesized
that increased FDG uptake in VTs is caused by urine. Urine
may reach the VT by capillary effect via its cotton string or
its proximity to the voiding pathway.
Although substantial FDG activity in a VT can be easily
localized and identified in PET/CT examinations, high FDG
uptake in VTs may obscure FDG activity of surrounding
structures [6]. This has been described as a spillover
artefact and occurs in the surroundings of high activity
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structures in PET and SPECT [7, 8]. Therefore, especially
in women with cervicogenital carcinoma, this uptake
should be prevented. To facilitate local staging of cervical
cancer in MRI, several authors have proposed the use of
VTs to distend the vaginal vault during imaging [9, 10].
However, due to increased resolution of MRI imaging, the
use of VTs is no longer recommended [11]. The use of VTs
for local staging and follow-up of cervicogenital malig-
nancy has not yet been reported for PET/CT, but in order to
analyse a potential benefit of VTs for PET/CT examinations
of cervicogenital malignancies, high FDG activities in the
VT must be prevented.
The aim of the present study was to determine whether
FDG uptake in VTs is caused by menstrual blood, urine
contamination or vaginal secretion and to find a way to
prevent it.
Materials and methods
Patients
This study was approved by the Institutional Review Board
of the hospital and consisted of a retrospective and a
prospective part. In the retrospective part, 685 PET/CT
exams of women 20–48 years old scanned between
3 January 2008 and 30 December 2009 were reviewed for
VT presence and position in relation to the pubococcygeal
line (PCL) as well as VT FDG activity. Medical charts were
reviewed with particular attention to obstetric history.
In the prospective part between February and April
2010, we recruited premenopausal women with known or
suspected malignancies who regularly used VTs during
menstruation and thus were familiar with their use.
Exclusion criteria were cervical or genital carcinoma. To
assess urine as a potential source of FDG activity in VTs,
commercial VTs with normal cotton strings and modified
VTs with non-absorbable strings were examined in non-
menstruating women. After having obtained written
informed consent, medical history was taken on the day
of examination, including last menstruation date and parity.
PET/CT acquisition and analysis
All women were examined using our standard protocol on a
dedicated PET/CT scanner (GE Healthcare Discovery ST
16 or Discovery VCT 64, 7–8 frames, frame time 1.5 or
2 min) with optional administration of 1 l dilute oral
contrast agent approximately 1 h before the scan, injection
of 350–370 MBq FDG 40–45 min prior to the examination
(approximate total dose equivalent for the entire PET/CT
examination=10 mSv) and voiding just before the exami-
nation to eliminate bladder activity [12].
In the retrospective analysis, PET/CT images were
analysed for the maximum standardized uptake value
(SUVmax) of VTs. The SUVmax (g/ml) was calculated by
dividing the maximum FDG uptake (kBq/ml) by the
injected dose (MBq) and multiplication with the lean body
weight (kg). Furthermore, the distance from the base of the
VT to the PCL was measured, with negative values
indicating a position above and positive values indicating
a position below the PCL (Fig. 1).
In the prospective part, women were provided with a
commercial VT (Ob® Regular, dimensions 5×1.3×1.3 cm,
Johnson & Johnson, New Brunswick, NJ, USA) and asked
to insert it. Every second VT was modified by replacing the
cotton string with a sterile, non-absorbent nylon monofila-
ment (Dermalon 3-0, Tyco Healthcare, Mansfield, MA,
USA). The investigators were blinded to string type. All
patients were asked to insert the VTs before injection. After
the FDG uptake phase and prior to imaging, patients were
asked to void with the VT in situ. PET/CT images then
were analysed for VT activity and position relative to the
PCL.
Analysis of the VT
After completing imaging, all VTs were weighed and
analysed for FDG activity by using an activity meter. The
change in weight was calculated by subtracting 2.9 g
(average weight of unused Ob® Regular VTs). VTs were
cut into equal thirds (base, middle and top), which were
Fig. 1 Sagittal FDG PET/CT through the pelvis demonstrating the
analysis of the VT position in a 37-year-old woman with breast
cancer. The perpendicular distance (x) from the base of the VT to the
PCL (bold white line) was determined, with negative values denoting
VT position above and positive values denoting VT position below
the PCL. U uterus, C cervix, B bladder, filled with urine with a high
FDG activity
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soaked separately for 3–4 h in 10 ml NaCl 9%. An aliquot
of this sample was then evaluated for creatinine concen-
tration using the kinetic Jaffe method [13].
Statistical analysis
An SUVmax greater than 3 g/ml was defined as positive
FDG uptake. An SUVmax greater than 2.5 g/ml in soft
tissue is considered to be abnormal [14]. However, due to
the proximity to the highly active bladder, background
uptake can be higher in the vaginal area. We therefore
selected a cutoff of 3 g/ml to prevent false-positive VTs.
Statistic evaluation was undertaken by means of the non-
parametric Mann-Whitney U test for unpaired, non-normal
distributed data and the Pearson chi-square test for binomial
or categorical data (contingency tables), as appropriate.
A p value less than 0.05 was considered statistically
significant (two-sided).
Results
In the retrospective arm, VTswere found in 38 of 685 evaluated
women, of which 17 (45%) demonstrated increased FDG
uptake. Patient details are listed in Table 1. Thirteen FDG-
positive VTs were located below the PCL (13±11.2 mm), one
7 mm above,and three VTs were just at the level of the PCL.
In contrast, 12 of the FDG-negative VTs were above and 9
slightly under the PCL (−1.4±6.9 mm) (Fig. 2a). A statisti-
cally significant positive correlation was found between
positive FDG uptake and position below the PCL (p=0.001).
Twenty-four premenopausal women were included in the
prospective study of which four were in the menstrual
phase (patient details listed in Table 1). In seven patients
(29%), VTs were FDG positive (SUVmax 18.8±11.9 g/ml),
none with blood traces evident at visual inspection. Five
FDG-positive VTs were localized below (20±7.5 mm), one
at the level of and one 3 mm above the PCL. In contrast, 9
of 17 inactive VTs were at the level of or above the PCL
Retrospective Prospective p
Number of patients 38 24 -
Age (years±SD) 36±8.4 38±8.5 0.175
Menstrual bleeding n.a. 4 (16.6%) -
Body mass index (kg/m2± SD) 23.7±4.9 22.5±4.8 0.731
Parity 0.7±1 0.6±0.84 0.664
Primary tumour
Breast cancer 13 7
GIST 1 1
Melanoma 10 6
Colon carcinoma 2 2
Lymphoma 6 4
Focal nodular hyperplasia 0 1
Bronchial carcinoma 0 2
Thyroid carcinoma 1 1
Osteosarcoma 1 0
Ewing’s sarcoma 1 0
Pharyngeal carcinoma 1 0
Infection 2 0
Table 1 Patient demographics
SD standard deviation, GIST
gastrointestinal stromal tumour
Fig. 2 PET/CT data analysis. Correlation between VT position and
FDG activity, illustrated with box plots for FDG-negative vs FDG-
positive VTs. a In the retrospective study (n=38) for VT position
above (negative) or below the PCL (mm) (p=0.001, Mann-Whitney U
test) and b analogous in the prospective part (p=0.039, Mann-
Whitney U test)
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(−6.6±5.7 mm) and 8 inactive VTs were slightly below the
PCL (6±4.7 mm) (Fig. 2b). A statistically significant
positive correlation was found between VT FDG uptake
and position below the PCL (p=0.039). Figure 3 illustrates
all seven FDG-active VTs of the prospective study and one
FDG-negative VT (Fig. 3a) for direct comparison. FDG
activity was found at the base of all seven positive VTs,
extending into the middle portion in two cases (SUVmax
Fig. 3 Sagittal fused PET/CT images through the pelvis of eight non-
menstruating women in the prospective study. a VT position relative
to the PCL in a patient with an FDG-negative VT (*), with its base
located at the level of the PCL (white line); creatinine concentration
was not measurable. b–h All seven FDG-positive VTs of the
prospective study had a high creatinine concentration, mainly at the
base (728±871 μmol/l). Five VTs were located clearly below the PCL
(b–f), one just at the level of the PCL (g) and one 3 mm above the
PCL (h)
Fig. 4 Box plots for correlation
of FDG activity in VTs with
age, BMI or height. Statistical
comparison with the Mann-
Whitney U test for FDG-
negative vs FDG-positive VTs
in the pooled data (n=62):
a for age (p=0.169), b BMI
(p=0.903) and c height
(p=0.453). No correlation
was found
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37.5 g/ml, 23.7 g/ml; Fig. 3b, c) and into the superior
portion in just one patient (SUVmax 24 g/ml; Fig. 3d). Of
these seven positive VTs, six had the original manufac-
turer’s cotton string in place (SUVmax 15.7±9.4 g/ml),
while one was modified (i.e. cotton string replaced by
nylon monofilament), with uptake at its base and middle
portion (SUVmax 37.5 g/ml; Fig. 3c). Of 24 women in the
prospective study, 4 had blood traces on their VTs without
increased FDG uptake.
Pooling the retrospective and prospective data resulted in
a total of 62 cases with FDG-active VTs. Thirty-four VTs
(54.8%) were located below the PCL, of which 18 (53%)
showed increased FDG uptake. On the other hand, 17 VTs
were located above the PCL, of which only 2 (11%) were
FDG positive. In the pooled data, no statistically significant
correlation was found regarding VT FDG uptake and age
(p=0.169), body mass index (BMI) (p=0.285) or height
(p=0.453) (Fig. 4). The obstetric history of 38 (61%)
patients was known. No statistically significant correlation
was found for parity and VT FDG uptake (p=0.350,
Pearson chi-square). Table 2 shows the distribution of
FDG-positive and FDG-negative VTs.
In the prospective arm, activity in the VTs after removal
ranged from 202 to 919 kBq, with an average of 518±
308 kBq. Creatinine concentration was increased in all
seven FDG-positive VTs, which was consistently found at
the base, and to a lesser degree in the middle and superior
portions [base 728±871 μmol/l, middle 469±595 μmol/l,
top (positive only for five of seven VTs) 216±149 μmol/l].
In contrast, in none of the three FDG-negative VTs, which
served as negative controls, were creatinine concentrations
within detectable limits (<18 μmol/l). A high correlation
was noted between the SUVmax and VT creatinine concen-
tration (p<0.001, R2=0.772, y=0.016x+2.842) (Fig. 5a).
Active VTs showed a significantly greater increase in weight
after use (3.416±2.478 g, range 1.35–8.5 g) compared to
FDG-negative VTs (0.501±0.311 g, range 0.026–1.032 g;
p<0.001) (Fig. 5b). Calculating with a specific gravity of
1 g/ml for urine, and subtracting 0.5 g for vaginal secretion
(i.e. average increase in weight of FDG-negative VTs), the
average absorbed urinary volume is estimated at 2.8–2.9 ml,
with a maximum of 7.97 ml.
Discussion
This study provides strong evidence that urinary contami-
nation is the cause of FDG-positive VTs in PET/CT
scanning. Particularly in non-menstruating women, creati-
Table 2 Previous vaginal delivery versus FDG activity in VTs
Parity 0 Parity ≥ 1 Total
No FDG activity in VTs 13 7 20
FDG activity in VTs 9 9 18
Total 22 16 38
p=0.350 (Pearson chi-square test)
Fig. 5 Results of the VT analysis regarding creatinine concentration
and weight. a Correlation between FDG uptake and creatinine
concentration in ten VTs. All seven VTs with increased FDG uptake
(SUV >3 g/ml) had increased creatinine concentrations which
correlated well with FDG uptake/SUVmax. Three VTs with an SUV
<3 g/ml served as negative controls and were not found to have a
creatinine concentration within detectable limits (<18 μmol/l). b Box
plot illustrating weight increases after use for all patients without
menses, with no overlap between FDG-negative and FDG-positive
VTs and a significant correlation between increased weight and
activity (p<0.001)
94 Eur J Nucl Med Mol Imaging (2011) 38:90–96
nine concentration and FDG uptake in VTs correlated well
with the increase in weight of up to 8.5 g, proving the
presence of urine in the VT. In addition, the local
distribution of creatinine mainly at the base with lower
concentration in the middle or top of the VT correlated well
with the imaging findings, which always showed FDG
accumulation at the base. While urinary contamination of
VTs is not a priori expected, the increased FDG uptake in
VTs cannot be explained by menstrual blood, because of
dominant radioactivity in the caudal portions of the VTs
and because seven non-menstruating women also had FDG-
positive VTs. If vaginal secretion of FDG or F-active
metabolites were causative for VT activity, one would first
expect an equal activity distribution over the whole surface
of the VTs and therefore also in their top portions. Second,
FDG activity would be expected to be increased in the
vaginal lumen even in patients without VTs. Third, vaginal
secretion has an average glucose concentration of approx-
imately 5.0 mM, which is in the range of typical fasting
blood sugar levels. Hence, VT FDG concentration in
vaginal secretion should not be higher than blood pool
values (SUV 1.5–2.5 g/ml) [15].
The prevalence of involuntary leakage of urine for
premenopausal women aged 20–44 years is 9–23% and is
mainly due to stress urinary incontinence [16]. Involuntary
leakage in premenopausal women during the uptake phase
in a resting supine position without physical activity is
unlikely. Therefore, contamination of the VT is likely to
occur during voiding, either by direct contamination due to
VT positioning facilitating its contact with urine or by
capillary action of the VT string positioned in the voiding
pathway.
Direct contamination can only occur when at least a part
of the VT is in the voiding pathway. A good correlation was
seen between FDG uptake and position of the VT base at or
below the PCL. Therefore, such a caudal position seems to
be a risk factor for direct urinary contamination. Possible
explanations for a low VT position could be poor place-
ment of the VT or a weakness of the pelvic floor, and
therefore related to age or parity. However, we could not
show such correlations in our premenopausal collective.
A contributory factor of capillary action by the cotton
string is questionable. The observations in the prospective
group suggest that a modified string could reduce contam-
ination since only one modified and six normal VTs
showed increased activity. However, sheer capillary action
of the cotton strings cannot explain quantities of VT urine
content of up to 8 ml.
Very intense FDG activity can obscure adjacent
structures due to the so-called blooming or spillover
artefact [6–8]. Especially in women with cervicogenital
malignancies such artefacts could impair diagnostic
accuracy. In addition, also the incidental finding of
pathological activity in the cervical region could be
obscured by a highly FDG-avid VT. Therefore, all
possible measures should be taken to avoid FDG uptake
in VTs. As a consequence of the evidence that urinary
contamination during voiding is the reason for FDG
accumulation in VTs, we suggest three options to prevent
this uptake. Firstly, the VT has to be replaced immediately
before PET/CT and after voiding. Secondly, the VT has to
be removed prior to PET/CT, or thirdly VTs will have to
be designed differently.
The fact that urine can be found in 39% of the VTs after
voiding raises also concerns for the general female
population using VTs. What impact this urine contamina-
tion can have on comfort and hygiene, however, cannot be
answered with the present study and needs further inves-
tigations.
A limitation of this study is the incomplete obstetric and
gynaecologic history for the patients in the retrospective
study, in particular, regarding the regular use of VTs and
parity. This study cannot differentiate between different
factors which may contribute to low VT position, such as
improper VT insertion, caudal migration in a resting state or
during voiding, or pelvic floor weakness. Therefore, further
investigations regarding VT position and the voiding
dynamics of the pelvic floor would be needed.
In conclusion, frequently observed FDG uptake in VTs
is not caused by menstrual blood, but is due to urinary
contamination which is related to VT position below the
PCL leading to direct contact with the voiding pathway.
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